Publication: Clinical applications of noncoding RNAs in lung cancer patients
Loading...
Date
2022
Journal Title
Clinical Applications of Noncoding RNAs in Cancer
Journal ISSN
Volume Title
Publisher
Elsevier
Abstract
Lung cancer is the most diagnosed and the foremost cause of cancer-associated deaths worldwide. In recent few decades, noncoding RNAs (ncRNAs) are identified as a key genomic product, which tightly control the expression of various target genes involved in the regulation of various crucial cellular and pathological processes. Interestingly, the role of aberrant expression of ncRNAs has been reported in the development and progression of various cancers, including lung cancer. They are considered one of the promising biomarkers for the prognosis and diagnosis of lung cancer. Furthermore, ncRNAs are not only identified as potential predictive markers for chemo- and radioresistance in lung cancer but also have a great therapeutic value in designing novel therapeutic regimens against lung cancer. The present chapter provides detailed information regarding the role of ncRNAs in the pathogenesis of lung cancer along with their clinical applications. � 2022 Elsevier Inc. All rights reserved.
Description
Keywords
Chemoresistance, Diagnosis, LncRNA, Lung cancer, MiRNA, Prognosis, Radioresistance